Physician profile
Weldon L Smith
NPI 1063425155
$5,330.37
in general payments reported to CMS, 2019-2025
40 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,396 · 2020: $323 · 2021: $742 · 2022: $604 · 2023: $533 · 2024: $620 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,265.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $912.43 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $588.10 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $418.03 | 2019-2022 | |
| Amgen INC. | $410.81 | 2019-2025 | Evenity, Repatha, Prolia |
| Glaxosmithkline, LLC. | $335.09 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $319.59 | 2019-2025 | Veozah |
| Pfizer INC. | $269.17 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $262.36 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $149.79 | 2019-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.27 | 2019-2025 | |
| Abbvie INC. | $134.67 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $131.26 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $129.82 | 2023-2024 | Spravato |
| Sanofi-Aventis U.S. LLC | $118.87 | 2020-2025 | |
| Lilly USA, LLC | $93.87 | 2022-2025 | Kisunla, Amyvid, Jardiance |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weldon Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.